Current status of biomarkers for prostate cancer

Prostate cancer (PCa) is a leading cause of cancer-related death of men globally. Since its introduction, there has been intense debate as to the effectiveness of the prostate specific antigen (PSA) test as a screening tool for PCa. It is now evident that the PSA test produces unacceptably high rate...

Full description

Saved in:
Bibliographic Details
Published inInternational Journal of Molecular Sciences Vol. 14; no. 6; pp. 11034 - 11060
Main Authors Velonas, Vicki M, Woo, Henry H, dos Remedios, Cristobal G, Assinder, Stephen J
Format Journal Article Book Review
LanguageEnglish
Published Switzerland MDPI AG 24.05.2013
Molecular Diversity Preservation International (MDPI)
Subjects
Acid Phosphatase
antibody microarrays
Biomarkers, Tumor - metabolism
diagnostic biomarkers
genomics
Humans
Male
prostate cancer
Prostate-Specific Antigen - metabolism
Prostatic Neoplasms - diagnosis
Protein Tyrosine Phosphatases - metabolism
proteomics
PSA
Review
Online AccessGet full text

Cover

More Information
Summary:Prostate cancer (PCa) is a leading cause of cancer-related death of men globally. Since its introduction, there has been intense debate as to the effectiveness of the prostate specific antigen (PSA) test as a screening tool for PCa. It is now evident that the PSA test produces unacceptably high rates of false positive results and is not prognostic. Here we review the current status of molecular biomarkers that promise to be prognostic and that might inform individual patient management. It highlights current efforts to identify biomarkers obtained by minimally invasive methods and discusses current knowledge with regard to gene fusions, mRNA and microRNAs, immunology, and cancer-associated microparticles.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms140611034